|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Plasma and sputum HMGB1 levels did not correlate to disease severity (pneumonia severity index or presence of sepsis), but high sputum HMGB1 level was correlated to pneumococcal aetiology (p = 0.002).
|
30194360 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In an experimental rat model of sepsis caused by cecal ligation and puncture (CLP), Gu-4 administration prominently attenuated lung injury and improved the survival of the septic animals, which was positively correlated with the decrease of the serum HMGB1 level.
|
24603876 |
2014 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
It is interesting that the patterns of change of HMGB1 and SAA over time were distinctive for SIRS and SEPSIS groups.
|
28680349 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, we suggested that miR-181a-5p may play a role in regulating DC responses to HMGB1 and serve as evidence indicating that novel therapies targeting miRNAs may be useful for treating immune dysfunction in the setting of sepsis.
|
28947753 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High-mobility group box 1 (HMGB1) is a nuclear protein that has been found to be a critical mediator of lethality in endotoxemia and sepsis.
|
19097991 |
2009 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High mobility group box 1 (HMGB1) plays a central role in the pathogenesis of sepsis and multiple organ dysfunction syndromes.
|
26632390 |
2016 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Emodin-6-O-β-D-glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo.
|
23146691 |
2013 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Collectively, the present study indicates that PBX 3'UTR may induce inflammatory responses and sepsis via acting as a competing endogenous RNA for HMGB1.
|
29484406 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The ubiquitous nuclear protein, high mobility group box 1 (HMGB1), is released by activated macrophages and human umbilical vein endothelial cells (HUVECs) and functions as a late mediator of experimental sepsis.
|
26224030 |
2015 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
HMGB1 is implicated as a late mediator of sepsis and is also involved in inflammatory and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.
|
24809802 |
2014 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data reveal that H<sub>2</sub> gas could suppress lung injury in septic mice through regulation of HO-1 and HMGB1 expression and that Nrf2 plays a main role in the protective effects of H<sub>2</sub> gas on lung damage caused by sepsis.
|
30660872 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
M-BSA ameliorated LPS-induced sepsis and dextran sulfate sodium (DSS)-induced colitis models in which HMGB1 has been shown to play progressive roles.
|
28338748 |
2017 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, simvastatin effectively reduced the intestinal levels of tumor necrosis factor α, interleukin-6, high-mobility group box 1, and malondialdehyde and increased the activity of superoxide dismutase in rats with sepsis.
|
30463769 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that HMGB1 accumulation in the late phase of sepsis plays a specific role in the development of postsepsis immunosuppression and specifically affects neutrophil-dependent antibacterial defense mechanisms.
|
27965385 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High Mobility Group Box-1 (HMGB1) is a non-histone nuclear protein that has been implicated in many pathological processes, from sepsis to ischemia.
|
31835864 |
2019 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, rTM administered prior to or after LPS suppressed the level of pro-inflammatory cytokine TNF-α in sera at 1-3 h after LPS injection, whereas only the administration of rTM after LPS suppressed the levels of HMGB1 and nucleosome (late-phase mediators of sepsis) (9-12 h) in sera after the LPS injection.
|
28587368 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
HMGB-1 is considered as an essential facilitator in diseases such as sepsis, collagen disease, atherosclerosis, cancers, arthritis, acute lung injury, epilepsy, myocardial infarction, and local and systemic inflammation.
|
31215389 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The pooled mean differences in biomarker concentration (nonsurvivors - survivors), measured at onset of sepsis, are listed as follows: (1) Ang-1: - 2.9 ng/ml (95% CI - 4.1 to - 1.7, p < 0.01); (2) Ang-2: 4.9 ng/ml (95% CI 2.6 to 7.1, p < 0.01); (3) HMGB1: 1.2 ng/ml (95% CI 0.0 to 2.4, p = 0.05); (4) sRAGE: 1003 pg/ml (95% CI 628 to 1377, p < 0.01); (5) sTREM-1: 87 pg/ml (95% CI 2 to 171, p = 0.04); (6) suPAR: 5.2 ng/ml (95% CI 4.5 to 6.0, p < 0.01).
|
31705327 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to quantify measures of endothelial function, including markers of activation (endocan, Angiopoietin-2 [Ang-2], and von Willebrand Factor), endogenous anticoagulants (tissue factor pathway inhibitor and protein C), and damage-associated factors (High Mobility Group Box 1 [HMGB-1]) in the plasma of patients with sepsis and DIC, and to determine the relationship of these factors with severity of illness and outcome.
|
31140293 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High mobility group box 1 (HMGB1) is a proinflammatory cytokine associated with death from sepsis and other inflammatory diseases.
|
30780033 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These observations demonstrate that specific inhibition of endogenous HMGB1 therapeutically reverses lethality of established sepsis indicating that HMGB1 inhibitors can be administered in a clinically relevant time frame.
|
14695889 |
2004 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The mechanism of immunomodulation by mung bean has not been described until today except for a report which identified HMGB1 suppression as a pathway underlying the protective effect against sepsis.
|
28373035 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Both HMGB1 and IL-1β have been found to play critical roles in sepsis and post-burn immune dysfunction.
|
29601597 |
2018 |
|
Sepsis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In sepsis and septic shock, pathogen-associated molecular pattern molecules (PAMPS), such as bacterial exotoxins, cause direct cellular damage and/or trigger an immune response in the host often leading to excessive cytokine production, a maladaptive systemic inflammatory response syndrome response (SIRS), and tissue damage that releases DAMPs, such as activated complement and HMGB-1, into the bloodstream causing further organ injury.
|
29370247 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The exogenous application of the anti-HMGB1 neutralizing antibody improved efferocytosis, vascular integrity and survival rate in sepsis.
|
30235477 |
2018 |